KNSA — Kiniksa Pharmaceuticals International, plc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1730430 · United Kingdom
Last close
$95.11
Market Cap
$4.64B
52W High
$99.31
52W Low
$37.02
ADV30
824,335
Next earnings
2026-10-27

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 285,970,000 152,383,000 54,236,000 47,345,000 983,243,000 81,660,000 273,050,000
Jun 2026 243,600,000 131,959,000 27,194,000 25,432,000 896,110,000 175,677,000 241,961,000
Mar 2026 214,266,000 117,893,000 29,267,000 22,592,000 825,280,000 189,952,000 219,593,000
Dec 2025 202,127,000 111,152,000 19,768,000 14,199,000 763,633,000 165,596,000 196,027,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$198,835,000
Investing CF
$-314,874,000
Financing CF
$22,841,000
CapEx
$-1,637,000
Dividends Paid
—
Buybacks
$-15,777,000
EPS Diluted TTM
$1.30
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-366,769,000
Inventory
$108,028,000
Receivables
$30,779,000
ST Investments
$487,098,000
EBIT TTM
$130,465,000
Pretax Income TTM
$146,152,000
Interest Exp TTM
—
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$945,963,008
EBITDA
$132,362,000
Free Cash Flow
$135,869,632
Enterprise Value
$6,686,580,224
Total Cash
$568,758,016
Total Debt
$7,884,000
Shares Out
48,836,965
Trailing EPS
$1.32
Book Value
$9.05
ROE
17.6%
ROA
9.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 677,564,000 77,221,000 59,005,000 763,633,000 196,027,000 567,606,000 137,985,000
Dec 2024 423,239,000 -45,616,000 -43,193,000 580,553,000 142,117,000 438,436,000 25,689,000
Dec 2023 270,259,000 -25,196,000 14,084,000 526,322,000 87,483,000 438,839,000 13,301,000
Dec 2022 220,180,000 9,773,000 183,363,000 459,672,000 63,523,000 396,149,000 5,807,000

TTM Snapshot

Revenues TTM
$840,848,000
NetIncome TTM
$80,658,000
OpCashFlow TTM
—
Assets (Latest)
$896,110,000
Forward EPS
$2.18

Max Pain — expiry 2026-12-18

max pain strike: $75.00 · spot: $95.05 · call oi: 2,205 · put oi: 414
Expected Move to 2026-12-18: ±$11.25 (11.84%) — implied range $83.80 – $106.30 · ATM straddle on $95.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EWTX Edgewise Therapeutics, Inc. $4.60B $42.04 —
GIKLY Grifols SA $4.69B $5.55 —
IONS IONIS PHARMACEUTICALS INC $4.49B $26.96 —
COGT Cogent Biosciences, Inc. $4.85B $27.85 —
ERAS Erasca, Inc. $4.87B $13.89 —

News headlines (Yahoo Finance, 1h cache)

Top pharma stock to watch: TD Cowen’s pick
2026-11-18 20:20 · Yahoo
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
2026-11-11 21:01 · Yahoo
Kiniksa (KNSA) Stock Jumps As Q3 Results Fuel Growth Debate
2026-10-28 07:11 · Yahoo
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
2026-10-27 18:11 · Yahoo
Kiniksa (KNSA) Q3 2026 Earnings Call Transcript
2026-10-27 16:43 · Yahoo
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
2026-10-27 16:04 · Yahoo
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
2026-10-27 11:50 · Yahoo
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
2026-10-27 11:30 · Yahoo
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
2026-10-22 20:01 · Yahoo
Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight
2026-10-14 20:08 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.